300702SZSE
🚨 Material Event

Announcement on Wholly-Owned Subsidiary's Drug Approval

✨ AI Summary

Zhejiang Tianyu Pharmaceutical Co., Ltd. announces its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., has received approval from the NMPA for Apalutamide Tablets. This expands the company's product portfolio, potentially increasing revenue and market competitiveness, though future sales are subject to market conditions.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Zhejiang Tianyu Pharmaceutical Co., Ltd. Announcement on Wholly-Owned Subsidiary's Drug Approval

The Board of Directors and all directors of the Company guarantee that the announcement content is free from false representations, misleading statements, or material omissions, and that they will bear individual and joint legal responsibility for the authenticity, accuracy, and completeness of the content.

Zhejiang Tianyu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company")'s wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd. (hereinafter referred to as "Nuode Pharmaceutical"), recently received the "Drug Registration Certificate" for Apalutamide Tablets, approved and issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). The relevant situation is hereby announced as follows:

I. Drug Information

  1. Basic Drug Information

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.